Cyclophosphamide injection

DRUG6 trials

Conditions

AMLAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaArachnoiditis; Tuberculous (Etiology)B-cell Non Hodgkin LymphomaBreast CancerChronic Lymphocytic LeukemiaHodgkin Lymphoma

Early Phase 1

Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)

Enrolling by invitationNCT06499025

BGI, ChinaAML, Neoantigen, t(8;21)

Start: 2024-02-01End: 2027-12-30Target: 16Updated: 2025-08-28

Phase 1

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

RecruitingNCT05702853

Medical University of South CarolinaB-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia

Start: 2023-11-06End: 2026-12-30Target: 27Updated: 2026-03-27

PTCy and ATG for MSD and MUD Transplants

RecruitingNCT06299462

Instituto Nacional de Cancer, BrazilAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hodgkin Lymphoma +2

Start: 2024-06-14End: 2031-06-01Target: 50Updated: 2025-02-25

Phase 2

Cyclophosphamide in the Treatment of Refractory Proliferative Arachnoiditis in CNS Tuberculosis

NCT04620772

All India Institute of Medical SciencesArachnoiditis; Tuberculous (Etiology), Tubercular Meningitis, Tuberculosis

Start: 2021-01-01End: 2024-12-31Target: 40Updated: 2020-12-30

Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma

Not yet recruitingNCT05303727

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeuroblastoma

Start: 2022-08-31End: 2027-08-31Target: 64Updated: 2022-07-01

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

RecruitingNCT06107673

Hebei Medical University Fourth HospitalBreast Cancer

Start: 2023-09-30End: 2028-12-01Target: 144Updated: 2025-12-11

Related Papers

Adoptive T-cell therapy targeting a novel non-canonical neoantigen derived from a translated AML1-ETO lncrna shows clinical activity in a first-in-human trial for t(8;21) AML

Blood2025-11-03

A phase II trial comparing dalpiciclib in combination with letrozole versus standard chemotherapy as neoadjuvant therapy in patients with high-risk HR- positive HER-2 negative breast cancer: DARLING-02.